Trillium Asset Management LLC Trims Holdings in IQVIA Holdings Inc. $IQV

Trillium Asset Management LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 26.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,533 shares of the medical research company’s stock after selling 2,350 shares during the quarter. Trillium Asset Management LLC’s holdings in IQVIA were worth $1,029,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after buying an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. boosted its position in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares in the last quarter. Nordea Investment Management AB boosted its position in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares in the last quarter. American Century Companies Inc. boosted its position in IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock valued at $251,852,000 after purchasing an additional 40,699 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and set a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their price target on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Barclays lifted their target price on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Redburn Partners set a $214.00 target price on shares of IQVIA in a research note on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.94.

IQVIA Stock Performance

Shares of NYSE IQV opened at $210.19 on Thursday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a 50 day simple moving average of $198.53 and a two-hundred day simple moving average of $175.34. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $225.91. The stock has a market cap of $35.80 billion, a price-to-earnings ratio of 28.83, a PEG ratio of 2.36 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same period in the previous year, the business posted $2.84 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.